• JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
 
  Bookmark and Share
 
 
Master's Dissertation
DOI
10.11606/D.87.2018.tde-26022018-121443
Document
Author
Full name
Eduardo Alfredo Adami
Institute/School/College
Knowledge Area
Date of Defense
Published
São Paulo, 2017
Supervisor
Committee
Ho, Paulo Lee (President)
Astray, Renato Mancini
Pessoa Junior, Adalberto
Title in Portuguese
Desenvolvimento da produção da vacina contra uma possível gripe pandêmica A (H7N9).
Keywords in Portuguese
A(H7N9)
Pandemia
Vacina contra A(H7N9)
Abstract in Portuguese
No mês de março de 2013 foram reportados pela Organização Mundial da Saúde (OMS) os primeiros casos de infecções humana pelo vírus Influenza aviário A(H7N9). Em maio de 2017 já haviam sido registrados 1439 casos. As infecções em humanos causadas por este vírus são associadas a consideráveis níveis de mortalidade e morbidade. A vacinação é atualmente o meio mais efetivo para prevenir as infecções e as severas complicações na saúde humana causada pelo vírus da Gripe. Desenvolver e produzir vacinas contra a Gripe pandêmica é a estratégia principal para uma resposta contra a pandemia (WORLD HEALTH ORGANIZATION, 2005). Este projeto produziu os bancos de vírus H7N9, um lote piloto e três lotes industriais em condições (BPF) dos monovalentes utilizados para a produção da vacina contra a gripe pandêmica, A(H7N9). Estes lotes foram caracterizados, avaliados em relação aos padrões de qualidade e testados quanto a imunogenicidade em ensaios com camundongos.
Title in English
Desenvolvimento da produção da vacina contra uma possível gripe pandêmica A(H7N9).
Keywords in English
A (H7N9)
Pandemic
Vaccine against H7N9
Abstract in English
In March 2013 it was reported by the World Health Organization (WHO) the first cases of human infections with avian influenza virus A (H7N9). In May 2017 they had been registered 1439 cases. The infections in humans caused by this virus are associated with considerable morbidity and mortality levels. Vaccination is currently the most effective way to prevent infections and severe complications on human health caused by the flu virus. Developing and producing vaccines against pandemic influenza is the main strategy for a response to the pandemic (WORLD HEALTH ORGANIZATION, 2005). This project produce the seeds virus A(H7N9), a pilot batch and three industrial lots (GMP) of the monovalents used to produce the pandemic influenza vaccine against A(H7N9). These batches were characterized, evaluated for quality standards and tested for immunogenicity in mouse assay.
 
WARNING - Viewing this document is conditioned on your acceptance of the following terms of use:
This document is only for private use for research and teaching activities. Reproduction for commercial use is forbidden. This rights cover the whole data about this document as well as its contents. Any uses or copies of this document in whole or in part must include the author's name.
There are withheld file due to requirements (data publishing, patents or rights).
Release Date
2020-02-26
Publishing Date
2018-02-26
 
WARNING: Learn what derived works are clicking here.
All rights of the thesis/dissertation are from the authors
CeTI-SC/STI
Digital Library of Theses and Dissertations of USP. Copyright © 2001-2019. All rights reserved.